DOI: 10.4244/EIJV17I10A134

Percutaneous tricuspid valve annuloplasty: additional data and remaining questions

Nicole Karam1,2, MD, PhD; Jörg Hausleiter3,4, MD

Moderate to severe tricuspid regurgitation (TR) is common and associated with an increased risk of hospitalisation due to heart failure as well as cardiovascular mortality1,2. Tricuspid valve (TV) surgery is often a high-risk procedure with these patients due to late referrals, comorbidities (such as previous cardiac surgery), frailty and/or advanced age3,4. Transcatheter tricuspid valve repair (TTVR) was developed for patients with severe symptomatic TR who were deemed ineligible for cardiac surgery. Although several techniques are available, edge-to-edge repair is currently the most widely used TTVR technique5,6,7.

In this issue of EuroIntervention, Nickenig et al present the 30-day outcomes of the ongoing post-market TriBAND study in which direct annuloplasty TTVR was performed using the Cardioband™ tricuspid system (Edwards Lifesciences, Irvine, CA, USA)8. Of the 61 patients included in the study, 94% presented with at least severe TR. The mean tricuspid annular septolateral diameter was 45.5±4.5 mm and the left ventricular ejection fraction was 53.3±7.6%. The procedural time was 202.2±51.6 minutes. Device success (defined as successful device deployment and delivery system retrieval) was achieved in 96.7% of cases, and procedural success (30% reduction in the effective regurgitant orifice area [EROA]) in 83.9% of patients with available EROA (unreadable in 30 patients). Of the 52 patients with a 30-day follow-up, 74% were in New York Heart Association (NYHA) Functional Class I-II. There was a persistent post-procedural reduction in end-diastolic tricuspid septolateral annular diameter by 20%, and a reduction of TR to moderate or less in 59% at discharge and 69% at 30 days (p<0.001). Mid-right ventricular end-diastolic diameter, inferior vena cava diameter and right atrial volume decreased, while left ventricular stroke volume, estimated systolic pulmonary artery pressure and cardiac output increased. The clinical success rate (procedural success with no major adverse cardiac events [MACE] at 30 days), was 54.1% (data unavailable for 24 patients). All-cause mortality was 1.6%. There were right coronary artery (RCA) injuries requiring interventions in four patients (6.6%) as well as severe bleedings in seven patients (11.5%).

TTVR offers a great opportunity to treat moderate to severe TR in patients who are ineligible for TV surgery. While edge-to-edge repair is the most used technique, annuloplasty is a potential alternative, particularly in patients with large TV annuli. This first analysis of the ongoing TriBAND study, despite the missing echocardiographic data and incomplete 30-day follow-up (<2/3), shows the promising results achievable by experienced teams using the Cardioband tricuspid system in the commercial set-up. The results compare well with those of the TRI-REPAIR study8 and confirm the improvement in right ventricular and TV dimensions observed with edge-to-edge repair5,6,7.

Several issues still need to be addressed: 1) tools are needed to select the optimal technique –tricuspid annuloplasty versus edge-to-edge repair versus TV replacement– for a given patient. Characterisation of TV anatomies, including leaflet tethering, should be reported for patients undergoing TV annuloplasty to guide future patient selection for this therapy; 2) a relatively high rate of procedural and early complications, including RCA injury and bleedings, were observed in this study, despite careful selection in experienced centres. Hopefully, improvements in selection criteria, procedural planning, site experience, imaging techniques (including intracardiac echocardiography), as well as the introduction of the next-generation Cardioband tricuspid system, will result in fewer complications and radiation exposure with shorter procedural times; 3) the durability of TR reduction with the current Cardioband tricuspid system needs to be estimated, and the rate of screening failures reported, as long implants for very large annuli are not currently available; 4) it will be interesting to see how the results of this interim analysis compare with the final results of the TriBAND study, after the enrolment of the total planned cohort and the completion of follow-up.

In conclusion, this interim analysis of the TriBAND study confirms the positive results of the TRI-REPAIR study but shows the need for further optimisation of procedural duration and selection tools. The respective roles of edge-to-edge and direct annuloplasty in the TTVR arsenal remain to be defined, including in relation to percutaneous TV replacement.

Conflict of interest statement

N. Karam has received consultant fees from Abbott Vascular and Edwards Lifesciences, and a research grant from Edwards Lifesciences. J. Hausleiter has received research support, speaker honoraria from and serves as consultant for Abbott Vascular and Edwards Lifesciences.

Supplementary data

To read the full content of this article, please download the PDF.


References

Volume 17 Number 10
Nov 19, 2021
Volume 17 Number 10
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV16I15A219 Feb 5, 2021
Transcatheter tricuspid valve treatment: does annular reduction make a difference?
Praz F and Brugger N
free

Original Research

10.4244/EIJ-D-23-01033 Mar 3, 2025
Outcomes of tricuspid transcatheter edge-to-edge repair in subjects with endocardial leads
Goebel B et al

10.4244/EIJV11SWA37 Sep 17, 2015
Tricuspid valve interventions in 2015
Lauten A and Figulla HR
free

Editorial

10.4244/EIJ-E-25-00006 Mar 3, 2025
Tricuspid annuloplasty: a piece of the puzzle or the whole picture?
Nickenig G and Vogelhuber J
free

EXPERT REVIEW

10.4244/EIJ-D-18-00520 Sep 7, 2018
Transcatheter treatment of tricuspid regurgitation (focusing on current technologies)
Grasso C et al
free

EXPERT REVIEW

10.4244/EIJ-D-17_00487 Sep 24, 2017
Transcatheter tricuspid valve intervention: state of the art
Taramasso M and Maisano F
free
Trending articles
309.93

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
166.7

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
92.2

State-of-the-Art Review

10.4244/EIJ-D-20-01296 Aug 27, 2021
Management of cardiogenic shock
Thiele H et al
free
76

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
72.85

State-of-the-Art

10.4244/EIJ-D-24-00386 Feb 3, 2025
Mechanical circulatory support for complex, high-risk percutaneous coronary intervention
Ferro E et al
free
58.3

Clinical research

10.4244/EIJ-D-23-00344 Sep 18, 2023
Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
Sanchez-Luna JP et al
free
56.65

Clinical research

10.4244/EIJ-D-20-01155 Oct 20, 2021
A deep learning algorithm for detecting acute myocardial infarction
Liu W et al
free
33.9

CLINICAL RESEARCH

10.4244/EIJ-D-17-00381 Oct 11, 2017
Stent malapposition and the risk of stent thrombosis: mechanistic insights from an in vitro model
Foin N et al
free
33.65

State-of-the-Art

10.4244/EIJ-D-23-00606 Jan 1, 2024
Targeting inflammation in atherosclerosis: overview, strategy and directions
Waksman R et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved